P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
Active, not recruiting · NCT06468033 · Registry updated 2026-08-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, myeloproliferative neoplasm, primary myelofibrosis | Active, not recruiting | Phase 3 | 2026-08-13 | NCT06468033 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| PharmaEssentia | 11 |
73 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.